Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPhio Pharmaceuticals Corp

Phio Pharmaceuticals Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.8013 USD 0.00 ( 0.16%)
Last update at 2026-11-06T21:00:00Z
VOLUME
75612
Market Cap
3.56M

Momentum Score

…

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.75
Low
0.83
High
52 Week Price Range
0.50
Low
3.53
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Phio Pharmaceuticals is a clinical-stage biotechnology company developing oligonucleotide-based therapeutics with a proprietary delivery platform aimed at modulating immune response in oncology and other diseases. Long-term growth drivers include clinical trial progress, strategic partnerships or licensing, and potential expansion into additional indications and markets. Investors may find the company attractive for platform upside if development milestones and partnership strategies advance.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.80
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-7.01M
Debt / Equity
0.00
ROE
-116.60%
Net Debt
-8.46M
ROCE
-150.78%
Diluted EPS TTM
-2.56

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -11.48M -13.29M -8.79M -8.91M -7.36M
Net income -11.30M -13.21M -8.79M -8.84M -7.36M
Selling general administrative 4.45M 4.62M 4.36M 4.71M 3.18M
Gross profit - - 0.00M 0.02M 0.14M
Reconciled depreciation 0.19M 0.07M 0.07M 0.07M 0.08M
Ebit -11.65M -13.59M -8.79M -9.05M -7.45M
Ebitda -11.46M -13.51M -8.72M -8.99M -7.36M
Depreciation and amortization 0.19M 0.07M 0.07M 0.07M 0.08M
Non operating income net other - - - - 0.00M
Operating income -11.46M -13.51M -8.79M -8.99M -7.36M
Other operating expenses 11.46M 13.51M 8.79M 9.01M 7.50M
Interest expense 0.17M 0.01M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income - -0.01M - - -
Income tax expense -0.17M -0.07M 0.00M -0.07M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.02M 0.14M
Total operating expenses 11.46M 13.51M 8.79M 9.01M 7.50M
Cost of revenue - - - 4.30M 4.33M
Total other income expense net -0.02M 0.22M -0.00M 0.08M 0.00M
Net income from continuing ops -11.48M -13.29M -8.79M -8.91M -7.36M
Net income applicable to common shares - -13.29M -8.79M -8.91M -7.36M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 9.36M 12.81M 25.17M 15.74M 8.04M
Other current assets 0.83M 0.61M 0.62M 0.87M 0.32M
Total liab 1.63M 1.98M 3.24M 2.72M 2.29M
Total stockholder equity 7.73M 10.84M 21.93M 13.02M 5.75M
Other current liab 0.94M 0.89M 2.66M 0.10M 0.03M
Common stock - - 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -139.21M -128.38M -116.90M -103.61M -94.82M
Other assets 0.00M - 0.03M 0.00M 0.02M
Cash 8.49M 11.78M 24.06M 14.24M 6.93M
Total current liabilities 1.63M 1.80M 3.07M 2.20M 1.88M
Current deferred revenue - - - 1.25M 0.94M
Net debt -8.46M -11.48M -23.76M -13.60M -6.42M
Short term debt 0.04M 0.14M 0.12M 0.12M 0.11M
Short long term debt total 0.04M 0.30M 0.29M 0.64M 0.52M
Other stockholder equity 137.57M 139.22M 138.83M 116.63M 100.57M
Property plant equipment - - 0.42M 0.56M 0.21M
Total current assets 9.32M 12.45M 24.73M 15.16M 7.30M
Net tangible assets - - 21.93M 13.02M 5.75M
Long term debt - - - 0.23M -
Accounts payable 0.66M 0.78M 0.28M 0.73M 0.81M
Accumulated other comprehensive income 0.00M - - - -1.05M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -103.61M -94.82M
Non currrent assets other 0.00M 0.02M 0.03M 0.02M 0.02M
Non current assets total 0.04M 0.37M 0.44M 0.57M 0.74M
Capital lease obligations 0.04M 0.17M 0.29M 0.41M 0.52M
Long term debt total - - - 0.23M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.12M -0.05M -0.02M -0.07M -0.01M
Change to liabilities - -0.45M -0.08M 0.00M -0.52M
Total cashflows from investing activities - -0.05M -0.02M -0.07M -0.01M
Net borrowings - - 0.20M -0.01M -0.01M
Total cash from financing activities -0.03M 21.72M 16.13M 0.77M 18.82M
Change to operating activities - 1.44M -0.25M -0.47M -0.56M
Net income -11.48M -13.29M -8.79M -8.91M -7.36M
Change in cash -12.28M 9.81M 7.31M -7.95M 11.30M
Begin period cash flow 24.11M 14.29M 6.98M 14.93M 3.63M
End period cash flow 11.83M 24.11M 14.29M 6.98M 14.93M
Total cash from operating activities -12.13M -11.86M -8.80M -8.64M -7.52M
Issuance of capital stock 0.00M 19.58M 12.09M 0.78M 18.72M
Depreciation 0.19M 0.07M 0.07M 0.07M 0.08M
Dividends paid - - 4.09M 0.00M -
Sale purchase of stock - - -0.01M 0.00M 0.00M
Other cashflows from financing activities 0.00M 2.15M 8.17M -0.00M 0.10M
Change to netincome - 0.36M 0.25M 0.41M 0.28M
Capital expenditures 0.12M 0.05M 0.02M 0.07M 0.01M
Cash flows other operating - - -0.55M -0.21M -0.00M
Cash and cash equivalents changes - - 7.31M -7.95M 11.30M
Change in working capital -1.26M 0.99M -0.33M -0.21M -0.52M
Stock based compensation 0.41M 0.48M 0.14M 0.30M 0.28M
Other non cash items - 0.12M 0.11M 0.11M -12.36M
Free cash flow -12.25M -11.91M -8.82M -8.72M -7.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PHIO
Phio Pharmaceuticals Corp		 0.00
0.16%		 0.80 - 0.31 48.01 0.40 172.20 0.51
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

257 Simarano Drive, Marlborough, MA, United States, 01752

508 767 3861

https://www.phiopharma.com

8

Name Title Year Born
Mr. Robert J. Bitterman Interim Exec. Chairman 1951
Dr. Geert Cauwenbergh Dr., Med.Sc., Ph.D. Interim Principal Exec. & Financial Officer and Director 1954
Ms. Caitlin Kontulis VP of Fin. & Admin. and Sec. 1986
Mr. Robert J. Bitterman President, CEO & Chairman 1951
Ms. Caitlin Kontulis VP of Finance & Administration and Secretary 1986
Ms. Linda M. Mahoney Senior Vice President of Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…